These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 37869783)

  • 1. Safety of current treatment options for NTRK fusion-positive cancers.
    Yang AT; Laetsch TW
    Expert Opin Drug Saf; 2023; 22(11):1073-1089. PubMed ID: 37869783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
    Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and treatment patterns of patients with
    Willis C; Au T; Hejazi A; Griswold C; Schabath MB; Thompson J; Malhotra J; Federman N; Ko G; Appukkuttan S; Warnock N; Kong SX; Hocum B; Brixner D; Stenehjem D
    J Manag Care Spec Pharm; 2024 Jul; 30(7):672-683. PubMed ID: 38950155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
    Blauel ER; Laetsch TW
    Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS; Lassen U
    Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
    Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
    Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
    Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N; McDermott R
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases.
    Cipri S; Fabozzi F; Del Baldo G; Milano GM; Boccuto L; Carai A; Mastronuzzi A
    Front Oncol; 2023; 13():1235794. PubMed ID: 38144536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
    Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
    Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
    BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R; Depetris I; Satolli MA
    Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
    [No Abstract]   [Full Text] [Related]  

  • 15. NTRK fusions in lung cancer: From biology to therapy.
    Harada G; Santini FC; Wilhelm C; Drilon A
    Lung Cancer; 2021 Nov; 161():108-113. PubMed ID: 34563714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
    Harada G; Drilon A
    Cancer Genet; 2022 Jun; 264-265():33-39. PubMed ID: 35334340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW; Hong DS
    Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW; Hawkins DS
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):1-10. PubMed ID: 30350734
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
    Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
    PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.